Akynzeo received U.S. Food and Drug Administration (FDA) approval on October 10, 2014 [1]. This approval was for the treatment of chemotherapy-induced nausea and vomiting (CINV) [1].
What is Akynzeo used for?
Akynzeo is a combination antiemetic drug used to prevent both acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy [2]. It works by blocking the action of two key receptors involved in the vomiting reflex: substance P at the neurokinin-1 (NK1) receptor and serotonin at the 5-HT3 receptor [3].
How does Akynzeo work?
Akynzeo is a fixed-dose combination of netupitant, a selective NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist [3]. Netupitant targets substance P, a neurotransmitter that plays a significant role in delayed CINV. Palonosetron targets serotonin, which is primarily involved in acute CINV [3]. By addressing both receptors, Akynzeo offers a dual mechanism of action to provide comprehensive protection against CINV [3].
What is the active ingredient in Akynzeo?
The active ingredients in Akynzeo are netupitant and palonosetron [3].
Who makes Akynzeo?
Akynzeo was developed by Eisai Inc. [4].
When does the patent for Akynzeo expire?
Information regarding the specific patent expiration dates for Akynzeo is available through resources like DrugPatentWatch.com [5]. Generally, patent protection for drugs can vary, and multiple patents may cover different aspects of a medication [5].
Are there other drugs like Akynzeo?
Yes, there are other antiemetic drugs used to manage CINV. These include other NK1 receptor antagonists, 5-HT3 receptor antagonists, and corticosteroids, often used in combination regimens [6]. Palonosetron (Aloxi) itself is a widely used 5-HT3 receptor antagonist [6].
What are the side effects of Akynzeo?
Common side effects of Akynzeo include constipation, fatigue, and headache [4]. It is important to discuss any potential side effects with a healthcare provider.
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-archive
[2] https://www.eisai.com/news/2014/pdf/news20141013.pdf
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313322/
[4] https://www.drugs.com/akynzeo.html
[5] https://drugpatentwatch.com/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971567/